Loveless Wealth Management LLC lessened its stake in shares of Johnson & Johnson (NYSE:JNJ – Get Rating) by 4.3% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 15,205 shares of the company’s stock after selling 675 shares during the quarter. Johnson & Johnson comprises 1.5% of Loveless Wealth Management LLC’s investment portfolio, making the stock its 17th biggest holding. Loveless Wealth Management LLC’s holdings in Johnson & Johnson were worth $2,695,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Several other large investors have also added to or reduced their stakes in JNJ. Norges Bank bought a new position in shares of Johnson & Johnson during the 4th quarter worth approximately $4,172,929,000. BlackRock Inc. increased its stake in shares of Johnson & Johnson by 2.6% during the 4th quarter. BlackRock Inc. now owns 200,021,352 shares of the company’s stock worth $34,217,654,000 after purchasing an additional 4,982,885 shares during the last quarter. GQG Partners LLC grew its stake in Johnson & Johnson by 1,109.4% in the 4th quarter. GQG Partners LLC now owns 3,954,383 shares of the company’s stock valued at $676,375,000 after buying an additional 3,627,424 shares in the last quarter. State Street Corp grew its stake in Johnson & Johnson by 1.8% in the 4th quarter. State Street Corp now owns 144,677,639 shares of the company’s stock valued at $24,750,004,000 after buying an additional 2,492,359 shares in the last quarter. Finally, Swiss National Bank grew its stake in Johnson & Johnson by 14.0% in the 1st quarter. Swiss National Bank now owns 11,402,516 shares of the company’s stock valued at $2,020,868,000 after buying an additional 1,396,500 shares in the last quarter. Institutional investors own 68.78% of the company’s stock.
Johnson & Johnson Stock Performance
Shares of NYSE JNJ opened at $167.13 on Friday. The company has a debt-to-equity ratio of 0.37, a quick ratio of 1.17 and a current ratio of 1.42. The company has a market cap of $439.41 billion, a P/E ratio of 24.33, a P/E/G ratio of 3.16 and a beta of 0.59. The firm’s fifty day moving average is $173.17 and its two-hundred day moving average is $174.39. Johnson & Johnson has a 52-week low of $155.72 and a 52-week high of $186.69.
Johnson & Johnson (NYSE:JNJ – Get Rating) last posted its earnings results on Tuesday, July 19th. The company reported $2.59 earnings per share for the quarter, topping analysts’ consensus estimates of $2.57 by $0.02. Johnson & Johnson had a net margin of 19.21% and a return on equity of 36.14%. The firm had revenue of $24.02 billion for the quarter, compared to the consensus estimate of $23.85 billion. During the same period in the previous year, the firm posted $2.48 EPS. The business’s quarterly revenue was up 3.0% on a year-over-year basis. As a group, analysts anticipate that Johnson & Johnson will post 10.05 EPS for the current fiscal year.
Johnson & Johnson Announces Dividend
The company also recently declared a quarterly dividend, which will be paid on Tuesday, September 6th. Investors of record on Tuesday, August 23rd will be paid a dividend of $1.13 per share. The ex-dividend date of this dividend is Monday, August 22nd. This represents a $4.52 dividend on an annualized basis and a dividend yield of 2.70%. Johnson & Johnson’s dividend payout ratio is presently 65.79%.
Wall Street Analysts Forecast Growth
A number of research analysts recently weighed in on JNJ shares. Daiwa Capital Markets started coverage on shares of Johnson & Johnson in a research note on Wednesday, June 22nd. They issued an “outperform” rating for the company. Wells Fargo & Company boosted their price target on shares of Johnson & Johnson from $190.00 to $195.00 and gave the company an “overweight” rating in a research report on Wednesday, July 13th. StockNews.com raised shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a report on Tuesday, May 17th. Morgan Stanley boosted their price target on shares of Johnson & Johnson from $173.00 to $174.00 and gave the stock an “equal weight” rating in a research note on Friday, July 8th. Finally, UBS Group lowered their price target on shares of Johnson & Johnson from $185.00 to $180.00 in a research note on Thursday, July 21st. Four research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, Johnson & Johnson presently has a consensus rating of “Moderate Buy” and an average target price of $189.89.
Insider Buying and Selling at Johnson & Johnson
In other news, EVP Kathryn E. Wengel sold 40,000 shares of the business’s stock in a transaction dated Friday, June 10th. The shares were sold at an average price of $173.00, for a total value of $6,920,000.00. Following the completion of the sale, the executive vice president now owns 71,311 shares in the company, valued at approximately $12,336,803. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. 0.35% of the stock is owned by corporate insiders.
Johnson & Johnson Profile
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company’s Consumer Health segment offers baby care products under the JOHNSON’S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.
Receive News & Ratings for Johnson & Johnson Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Johnson & Johnson and related companies with MarketBeat.com’s FREE daily email newsletter.